Skip to main content
Fig. 4 | Molecular Cancer

Fig. 4

From: A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer

Fig. 4

Chemoresistance of HCT116 IGF2BP2 wildtype (WT) and knockout (KO) cells in 2D cell culture. A-E Cell confluency was monitored using the IncuCyte®S3 system over 4 days. HCT116 WT cells and HCT116 IGF2BP2 KO cells were seeded 24 h prior treatment. The added compounds were 5-fluorouracil (A, 22.2 µM), oxaliplatin (B, 2.6 µM), gefitinib (C, 23.5 µM), regorafenib (D, 8.1 µM) and selumitinib (E, 7.4 µM). Confluency was normalized to the time of treatment (0 h). Each normalized value was subtracted from its vehicle control. Data are represented as means ± SEM, n = 3 (quadruplicates). Statistical significance was tested by one-way ANOVA. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001

Back to article page

Molecular Cancer

ISSN: 1476-4598